[{"id":"d0409497-b75d-44b0-85df-4030915dc145","acronym":"HS-10241-301","url":"https://clinicaltrials.gov/study/NCT06110663","created_at":"2023-11-01T15:12:24.088Z","updated_at":"2024-07-02T16:35:30.877Z","phase":"Phase 3","brief_title":"A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy","source_id_and_acronym":"NCT06110663 - HS-10241-301","lead_sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","biomarkers":" MET","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR T790M • MET positive","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR T790M • MET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • pemetrexed • Ameile (aumolertinib) • dalmelitinib (HS-10241)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 314","initiation":"Initiation: 12/30/2023","start_date":" 12/30/2023","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 02/28/2025","study_completion_date":" 02/28/2025","last_update_posted":"2023-11-01"},{"id":"a44fd9da-48a5-4030-9451-0e84dbc43d2f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05430386","created_at":"2022-06-24T15:56:28.883Z","updated_at":"2024-07-02T16:35:55.559Z","phase":"Phase 1","brief_title":"Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC","source_id_and_acronym":"NCT05430386","lead_sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","biomarkers":" MET","pipe":" | ","alterations":" EGFR L858R • EGFR exon 19 deletion • MET mutation • MET positive • EGFR T790M negative • EGFR mutation + MET-CEP7 fusion • MET positive + EGFR mutation","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR L858R • EGFR exon 19 deletion • MET mutation • MET positive • EGFR T790M negative • EGFR mutation + MET-CEP7 fusion • MET positive + EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ameile (aumolertinib) • dalmelitinib (HS-10241)"],"overall_status":"Recruiting","enrollment":" Enrollment 174","initiation":"Initiation: 01/05/2022","start_date":" 01/05/2022","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2023-02-14"},{"id":"304b1b2d-522f-4ef1-a082-41a9f63e4935","acronym":"","url":"https://clinicaltrials.gov/study/NCT03243643","created_at":"2021-01-18T16:01:31.878Z","updated_at":"2024-07-02T16:37:18.093Z","phase":"Phase 1","brief_title":"Tolerability, Safety, Pharmacokinetics and Efficacy of HS-10241 Single Agent or Combined With Apatinib in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT03243643","lead_sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","biomarkers":" MET","pipe":"","alterations":" ","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiTan (rivoceranib) • dalmelitinib (HS-10241)"],"overall_status":"Unknown status","enrollment":" Enrollment 80","initiation":"Initiation: 08/08/2017","start_date":" 08/08/2017","primary_txt":" Primary completion: 07/01/2019","primary_completion_date":" 07/01/2019","study_txt":" Completion: 12/01/2019","study_completion_date":" 12/01/2019","last_update_posted":"2017-09-08"},{"id":"70d12bc0-2116-4871-8e9d-2d4a1d101786","acronym":"","url":"https://clinicaltrials.gov/study/NCT02977364","created_at":"2021-01-18T14:38:17.876Z","updated_at":"2024-07-02T16:37:27.355Z","phase":"Phase 1","brief_title":"A Trial of C-met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumours","source_id_and_acronym":"NCT02977364","lead_sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","biomarkers":" MET","pipe":" | ","alterations":" MET positive","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dalmelitinib (HS-10241)"],"overall_status":"Unknown status","enrollment":" Enrollment 50","initiation":"Initiation: 11/01/2016","start_date":" 11/01/2016","primary_txt":" Primary completion: 11/01/2018","primary_completion_date":" 11/01/2018","study_txt":" Completion: 11/01/2021","study_completion_date":" 11/01/2021","last_update_posted":"2016-11-30"}]